Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 1
2020 1
2021 5
2022 4
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
GBD 2017 DALYs and HALE Collaborators. GBD 2017 DALYs and HALE Collaborators. Lancet. 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3. Lancet. 2018. PMID: 30415748 Free PMC article.
BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. ...
BACKGROUND: How long one lives, how many years of life are spent in good and poor health, and how the population's state of health an …
Monitoring B cell alloresponses in rats.
Steines L, Scharf M, Hoffmann P, Schuster A, Banas B, Bergler T. Steines L, et al. J Immunol Methods. 2022 Feb;501:113212. doi: 10.1016/j.jim.2021.113212. Epub 2021 Dec 29. J Immunol Methods. 2022. PMID: 34971633 Free article.
Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board.
Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, Rühlmann K, Flach M, Biro D, von Bergwelt-Baildon M, Holch J, Herold T, von Baumgarten L, Greif PA, Jeremias I, Wuerstlein R, Casuscelli J, Spitzweg C, Seidensticker M, Renz B, Corradini S, Baumeister P, Goni E, Tufman A, Jung A, Kumbrink J, Kirchner T, Klauschen F, Metzeler KH, Heinemann V, Westphalen CB. Heinrich K, et al. J Cancer Res Clin Oncol. 2023 May;149(5):1905-1915. doi: 10.1007/s00432-022-04165-0. Epub 2022 Jul 7. J Cancer Res Clin Oncol. 2023. PMID: 35796778 Free PMC article. Review.
Differentiation of Cerebral Neoplasms with Vessel Size Imaging (VSI).
Foda A, Kellner E, Gunawardana A, Gao X, Janz M, Kufner A, Khalil AA, Geran R, Mekle R, Fiebach JB, Galinovic I. Foda A, et al. Clin Neuroradiol. 2022 Mar;32(1):239-248. doi: 10.1007/s00062-021-01129-8. Epub 2021 Dec 23. Clin Neuroradiol. 2022. PMID: 34940899 Free PMC article.
Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Arlt B, Zasada C, Baum K, Wuenschel J, Mastrobuoni G, Lodrini M, Astrahantseff K, Winkler A, Schulte JH, Finkler S, Forbes M, Hundsdoerfer P, Guergen D, Hoffmann J, Wolf J, Eggert A, Kempa S, Deubzer HE. Arlt B, et al. Int J Cancer. 2021 Mar 1;148(5):1219-1232. doi: 10.1002/ijc.33423. Epub 2020 Dec 17. Int J Cancer. 2021. PMID: 33284994 Free article.
MAGIC: once upon a time in consent management-a FHIR® tale.
Bialke M, Bahls T, Geidel L, Rau H, Blumentritt A, Pasewald S, Wolff R, Steinmann J, Bronsch T, Bergh B, Tremper G, Lablans M, Ückert F, Lang S, Idris T, Hoffmann W. Bialke M, et al. J Transl Med. 2018 Sep 14;16(1):256. doi: 10.1186/s12967-018-1631-3. J Transl Med. 2018. PMID: 30217236 Free PMC article.
In the context of multi-centre research initiatives and a multitude of clinical and epidemiological studies scalable and automatable measures for digital consent management are required. Modular form, structure, and contents render a patient's consent reusable for varying …
In the context of multi-centre research initiatives and a multitude of clinical and epidemiological studies scalable and automatable measure …
The Impact of Upcoming Treatments in Huntington's Disease: Resource Capacity Limitations and Access to Care Implications.
Guttman M, Pedrazzoli M, Ponomareva M, Pelletier M, Townson L, Mukelabai K, Levine A, Nordström AL, Reilmann R, Burgunder JM. Guttman M, et al. J Huntingtons Dis. 2021;10(2):303-311. doi: 10.3233/JHD-200462. J Huntingtons Dis. 2021. PMID: 33843690 Free PMC article.
BACKGROUND: The most advanced disease-modifying therapies (DMTs) in development for Huntington's disease (HD) require intrathecal (IT) administration, which may create or exacerbate bottlenecks in resource capacity. ...
BACKGROUND: The most advanced disease-modifying therapies (DMTs) in development for Huntington's disease (HD) require intrathecal (IT …
12 results